SEC Filing Summary: Xcyte Therapies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xcyte Therapies, Inc. (Delaware) on January 3, 2006. The report addresses a corporate governance event regarding the composition of the Board of Directors' Audit Committee.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 8.01 (Other Events) and contains no financial statements or performance data.
Material Changes
The Board of Directors appointed Peter Langecker, a current Board member, to the Audit Committee. This appointment fills a vacancy created by the resignation of Jean Deleage from the Board of Directors on December 22, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific personnel change noted above.
Key Facts for Investor Verification
- Verify the effective date of Peter Langecker's appointment to the Audit Committee (January 3, 2006).
- Confirm the resignation date of Jean Deleage from the Board of Directors (December 22, 2005).
- Note that this filing does not disclose any financial performance or operational updates.